Joyn Bio signs $75M microbe licensing deal that could help Bayer

Through the partnership, Joyn Bio will get access to a catalog of thousands of different microbe strains, as well as NewLeaf’s manufacturing capabilities. The deal could significantly benefit Bayer AG, which owns 50 percent of Joyn Bio and is currently battling multiple lawsuits related to a chemical pesticide sold by its recently acquired subsidiary, Monsanto Co.